Problems With Developing New Antibiotics Case Study
Problems with Developing New Antibiotics
Since Alexander Fleming discovered penicillin in 1928, which is the first antibiotics. The use antibiotics skyrocket, a microorganism infection from a small cut that could have killed a person now could be solved in a matter of days. However, after this huge medical advancement which plummeted the percentage of death from any type of bacterial infection within the years of 1944 to 1972 the human life expectancy jumped by eight years. That huge difference mainly relying on the introduction of antibiotics. However, after all of the overuse of these antibiotics, the bacteria started to gain resistance. Which triggers a need for new types of antibiotics, this is where the pharmaceutical companies have a …show more content…
The next challenge is that antibiotics do not make as much profit as other types of medicine. For example, the longest period a person can go with antibiotics is seven to ten weeks at maximum. However, in many other diseases like depression, the client would sometimes need a lifelong prescription. Which then would result in all the huge pharmaceutical companies to stop any type of research toward new antibiotics. Which are extremely needed now that bacteria are gaining resistance to almost all of the antibiotics currently in the market. Another reason that this is happening is that in order to start a research project and finish it with new antibiotics in the market it would take around fifteen years. It is also estimated that throughout those fifteen years there are around one billion euros spent on that research project. In conclusion, there are many reasons for why there is a shortage of newly developed antibiotics in the market. Also, there are many more specific reasons that slow down the production of antibiotics. However, there are still solutions to this tremendous struggle. One simple act is to initiate public or private partnerships into starting new discovery projects so they could develop a continuous pipeline of new antibiotics in the future. When it is going to be most needed for newer types of resistant
Since Alexander Fleming discovered penicillin in 1928, which is the first antibiotics. The use antibiotics skyrocket, a microorganism infection from a small cut that could have killed a person now could be solved in a matter of days. However, after this huge medical advancement which plummeted the percentage of death from any type of bacterial infection within the years of 1944 to 1972 the human life expectancy jumped by eight years. That huge difference mainly relying on the introduction of antibiotics. However, after all of the overuse of these antibiotics, the bacteria started to gain resistance. Which triggers a need for new types of antibiotics, this is where the pharmaceutical companies have a …show more content…
The next challenge is that antibiotics do not make as much profit as other types of medicine. For example, the longest period a person can go with antibiotics is seven to ten weeks at maximum. However, in many other diseases like depression, the client would sometimes need a lifelong prescription. Which then would result in all the huge pharmaceutical companies to stop any type of research toward new antibiotics. Which are extremely needed now that bacteria are gaining resistance to almost all of the antibiotics currently in the market. Another reason that this is happening is that in order to start a research project and finish it with new antibiotics in the market it would take around fifteen years. It is also estimated that throughout those fifteen years there are around one billion euros spent on that research project. In conclusion, there are many reasons for why there is a shortage of newly developed antibiotics in the market. Also, there are many more specific reasons that slow down the production of antibiotics. However, there are still solutions to this tremendous struggle. One simple act is to initiate public or private partnerships into starting new discovery projects so they could develop a continuous pipeline of new antibiotics in the future. When it is going to be most needed for newer types of resistant